Optimizing Patient Outcomes in the Era of PCSK9 Inhibitor Therapeutics

http://academiccme.com/wp-content/uploads/2017/06/910713-125-x-125.jpg

Course Information

Therapautic Area: Cardiology
Format(s): Webcast
Credit(s): 2.00 AMA PRA Category 1 Credit(s)™
Activity Dates: June 29, 2017 - June 28, 2018

 

Program Overview

This activity will focus on the most current clinical trial data for optimizing patient outcomes in the era of PCSK9 inhibitor therapeutics presented as an Industry-Supported Symposium at the National Lipid Association 2017 Scientific Sessions. Expert faculty will utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision-making. The educational material of this symposium will provide vital information for lipidologsts to improve healthcare outcomes in their patients with statin intolerance, familial hypercholesterolemia and dyslipidemia.

Target Audience

Cardiologists, Lipidologists, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia.

Learning Objectives

  1. Review advances in LDL-C science and the role of LDL-C in CVD prevention
  2. Understand the current ACC/AHA/ESC/NLA guidelines for the management of patients with dyslipidemia.
  3. Analyze extended CVD Outcomes clinical trial data for PCSK9 inhibitor therapeutics.
  4. Apply newer scientific knowledge and data into personalized treatment plans for patients with statin intolerance, familial hypercholesterolemia, and dyslipidemia patients not at LDL-C goal.

Faculty

Picture1

Christopher P. Cannon, MD
Professor of Medicine
Harvard Medical School
Executive Director of Cardiometabolic Trials
Baim Institute for Clinical Research
Senior Physician, Cardiovascular Division
Brigham and Women’s Hospital
Boston, Massachusetts

 

Ballantyne Headshot high res

Christie M. Ballantyne, MD
Professor of Medicine
Baylor College of Medicine
Center for Cardiovascular Disease Prevention
Houston Methodist DeBakey Heart & Vascular Center
Baylor College of Medicine
Houston, Texas

 

Bays

Harold E. Bays, MD
Medical Director and President
Louisville Metabolic and Atherosclerosis Research Center
Louisville, Kentucky

 

 

G. Kees Hovingh, MD, PhD, MBAHovingh
Department of Vascular Medicine
Academic Medical Center
Amsterdam, Netherlands

 

 

 

Underberg high resJames A. Underberg, MD
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director Bellevue Hospital Lipid Clinic
President-Elect National Lipid Association
New York, New York

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

 

Faculty Relationship Identified With:
Christopher P. Cannon, MD Consultant/Advisor: Alnylam; Amgen, Inc.; Arisaph Pharmaceuticals, Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline plc.; Kowa Pharmaceuticals America, Inc.; LipoMedix; Merck & Co., Inc.; Pfizer Inc.;  Regeneron Pharmaceuticals, Inc.; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support: Arisaph Pharmaceuticals, Inc.; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Company; GlaxoSmithKline plc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Takeda Pharmaceuticals U.S.A., Inc.
Christie M. Ballantyne, MD Consultant/Advisor: Abbott Laboratories; Amarin Corp.; Amgen, Inc.; AstraZeneca; Eli Lilly and Company; Esperion Therapeutics, Inc.; Genzyme Corporation; Ionis Pharmaceuticals; Matinas BioPharma Holdings, Inc.; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Diagnostics; Sanofi-Synthelabo, Inc.
Grant/Research Support: Abbott Laboratories; Amarin Corp.; Amgen, Inc.; Eli Lilly and Company; Esperion Therapeutics, Inc.; Novartis AG; Pfizer Inc.; Otsuka America Pharmaceutical, Inc.; Regeneron Pharmaceuticals, Inc.; Roche Diagnostics; sanofi-aventis U.S. LLC.; Takeda Pharmaceuticals U.S.A., Inc.
Harold E. Bays, MD Consultant/Advisor: Alnylam, Amgen Inc.; AstraZeneca; Eli Lilly and Company; Esperion Therapeutics, Inc.; Ionis Pharmaceuticals; Janssen Global Services, LLC.; Kowa Pharmaceuticals America, Inc.; Merck & Co., Inc; Moderna Therapeutics; Novartis AG; Procter & Gamble; Regeneron Pharmaceuticals, Inc.; Sanofi; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd.
Grant/Research Support: Alere Inc. Company; Allergan; Amarin Corp.; Amgen Inc.; Arisaph Pharmaceuticals, Inc.; AstraZeneca; Bristol-Meyers Squibb Company; Catabasis; Cymabay Therapeutics, Inc.; Dr. Reddy; Eisai Co., Ltd.; Elcelyx Therapeutics, Inc.; Eli Lilly and Company; Esperion; Ferrer/Chiltern; Gemphire; Gilead; GlaxoSmithKline plc.; Janssen Global Services, LLC.; Johnson and Johnson Services, Inc.; Kowa Pharmaceuticals America, Inc.; Merck & Co., Inc.; Nektar; Nichi-Iko Pharmaceutical Co., Ltd.;, Novartis AG; Novo Nordisk A/S; Orexigen Therapeutics, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Selecta Biosciences, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; TIMI Pharmaceuticals, Inc.
Speaker’s Bureau: Amarin Corp.; Amgen Inc.; AstraZeneca; Eisai Co., Ltd.; Orexigen Therapeutics, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.
G. Kees Hovingh, MD, PhD, MBA Consultant/Advisor: Amgen, Inc; Aegerion Pharmaceuticals Inc.; AstraZeneca; Cerenis Therapeutics; Ionis Pharmaceuticals; Kowa Pharmaceuticals America, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
James A. Underberg, MD Consultant/Advisor: Aegerion Pharmaceuticals Inc.; Akcea Therapeutics; Amarin Corp.; Amgen, Inc.; Invitae Corporation; National Lipid Association.; Recombine
Grant/Research Support: Pfizer Inc.; Aegerion Pharmaceuticals Inc.
Speaker’s Bureau: Alexion Pharmaceuticals, Inc.; Amgen Inc.; AstraZeneca; Genzyme Corporation; Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; True Health Diagnostics

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Gilmartin; and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Amgen Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact admin@academiccme.com.
BUTTON


Provided by AcademicCME.

unnamed